First Department of Surgery, National & Kapodistrian University of Athens, Laikon General Hospital, Athens, Greece.
Department of Medical Oncology, Metaxa Cancer Hospital, Athens, Greece.
Immunotherapy. 2020 Feb;12(3):203-218. doi: 10.2217/imt-2019-0153. Epub 2020 Mar 24.
Esophageal cancer remains a global health concern with a dismal prognosis and an estimated 5-year survival rate of approximately 10-15%. Immunotherapy is a novel treatment approach representing an effective and promising option against several types of cancer. The development of new and efficacious immunotherapeutic strategies, such as adoptive cell therapy-based, antibody-based and vaccine-based therapies, aims to prevent immunological escape and modify immunological responses. In this review, we discuss the theoretical background and current status of immunotherapy for patients with esophageal cancer. We also present ongoing clinical trials and summarize key findings concerning survival and safety analyses.
食管癌仍然是一个全球性的健康问题，预后不良，估计 5 年生存率约为 10-15%。免疫疗法是一种新的治疗方法，代表了对抗多种癌症的有效和有前途的选择。正在开发新的有效的免疫治疗策略，如基于过继细胞疗法、抗体疗法和疫苗疗法，旨在防止免疫逃逸和改变免疫反应。在这篇综述中，我们讨论了食管癌患者免疫治疗的理论背景和现状。我们还介绍了正在进行的临床试验，并总结了有关生存和安全性分析的关键发现。
